Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Bounaix Morand du Puch, Christophe; Nouaille, Michelle; Giraud, Stéphanie; Labrunie, Anaïs; Luce, Sandrine; Preux, Pierre-Marie; Labrousse, François; Gainant, Alain; Tubiana-Mathieu, Nicole; Brun-Ly, Valérie; Valleix, Denis; Guillaudeau, Angélique; Mesturoux, Laura; Coulibaly, Béma; Lautrette, Christophe; Mathonnet, Muriel
• Is Part Of: Journal of translational medicine. Volume 14:Issue 1(2016)
• Page Start: 1
• Page End: 12
• Publication Date: 2016-12
• Subjects: Ex vivo model -- Colorectal cancer -- Oncogramme -- Primary culture -- Individualized tumor response testing -- Chemosensitivity and resistance assay; Medicine, Experimental -- Periodicals; Human experimentation in medicine -- Periodicals; Therapeutics -- Periodicals; 615.50724
• DOI: 10.1186/s12967-016-0765-4
• Languages: English
• ISSNs: 1479-5876

Abstract

Abstract Background Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to improve response rates is to develop chemosensitivity and resistance assays (CSRAs) efficiently assisting clinicians in treatment selection process, an already long preoccupation of oncologists and researchers. Several methods have been described to this day, none achieving yet sufficient reliability for recommended use in the clinical routine. Methods We led a pilot study on 19 metastatic CRC patients evaluating capacity of the Oncogramme, a standardized process using tumor ex vivo models, to provide chemosensitivity profiles and predict clinical outcome of patients receiving standard CRC chemotherapeutics. Oncogramme responses were categorized according to the method of percentiles to assess sensitivity, specificity and concordance. Results We report from a primary analysis a success rate of 97.4 %, a very good sensitivity (84.6 %), a below-average specificity (33.3 %), along with a global agreement of 63.6 % and a concordance between Oncogramme results and patients' responses (Kappa coefficient) of 0.193. A supplementary analysis, focusing on CRC patients with no treatment switch over a longer time course, demonstrated improvement in specificity and concordance. Conclusions Results establish feasibility and usefulness of the Oncogramme, prelude to a larger-scale trial. Advantages and drawbacks of the procedure are discussed, as well as the place of CSRAs within the future arsenal of methods available to clinicians to individualize treatments and improve patient prognosis. Trial registration : ClinicalTrials.gov database, registration number: NCT02305368